|
|
Volumn 18, Issue 11, 2012, Pages 1602-1606
|
|
Call in the backup
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ALB 111;
ANTISENSE OLIGONUCLEOTIDE;
NEUROPROTECTIVE AGENT;
OLESOXIME;
RG3039;
RNA;
SMNRX;
SURVIVAL MOTOR NEURON PROTEIN 1;
SURVIVAL MOTOR NEURON PROTEIN 2;
UNCLASSIFIED DRUG;
ANTISENSE THERAPY;
ARTICLE;
DRUG INDUSTRY;
GENE MUTATION;
HUMAN;
HUMAN GENOME;
MOTONEURON;
NONHUMAN;
PARALYSIS;
PHASE 1 CLINICAL TRIAL (TOPIC);
PRIORITY JOURNAL;
PROTEIN FUNCTION;
RNA PROCESSING;
SPINAL MUSCULAR ATROPHY;
CLINICAL TRIALS AS TOPIC;
DRUG INDUSTRY;
GENE DOSAGE;
GENOME, HUMAN;
HETEROZYGOTE;
HISTONE DEACETYLASE INHIBITORS;
HISTONE DEACETYLASES;
HUMANS;
INFANT, NEWBORN;
MOLECULAR TARGETED THERAPY;
MOTOR NEURONS;
MUSCULAR ATROPHY, SPINAL;
MUTATION;
SURVIVAL OF MOTOR NEURON 1 PROTEIN;
SURVIVAL OF MOTOR NEURON 2 PROTEIN;
|
|
EID: 84869193359
PISSN: 10788956
EISSN: 1546170X
Source Type: Journal
DOI: 10.1038/nm1112-1602 Document Type: Article |
|
Times cited : (7)
|
|
References (7)
|
